2023 World Conference on Lung Cancer (Posters)-P2.10. Updated Survival Data in Advanced ALK-rearranged Non-small Cell Lung Cancer Treated with Alectinib and Bevacizumab in the ALEK-B Study

P2.10. Updated Survival Data in Advanced ALK-rearranged Non-small Cell Lung Cancer Treated with Alectinib and Bevacizumab in the ALEK-B Study - PDF(Abstract)

Back to course

Pdf Summary

This abstract presents updated survival data from a study investigating the combination of alectinib and bevacizumab in patients with advanced ALK-rearranged non-small cell lung cancer (NSCLC). The study aimed to evaluate the efficacy and safety of this combination therapy in treatment-naïve patients.<br /><br />The results showed promising efficacy outcomes with a median progression-free survival (PFS) that was not reached at the time of data cut-off. The 24-month PFS rate was 77.8%. Overall survival (OS) at 24 months was 100%. Of the 41 evaluable patients, 36 reached a partial response and 5 had a complete response, resulting in an overall response rate (ORR) of 100%. The median percentage of tumor reduction was -84.9%. Deep responses were observed in 68.2% of patients, and 95.1% had responses of at least 50%. In patients with brain metastases, the intracranial (IC) response rate was 83.3%, and the 24-month IC event-free rate was 100%.<br /><br />The combination therapy was well-tolerated, with any grade adverse events occurring in 97.5% of patients. The most common adverse events were AST/ALT increase, diarrhea, proteinuria, and anemia. Grade 3 treatment-related adverse events occurred in 51.2% of patients, with AST/ALT increase and proteinuria being the most frequent. Bevacizumab was discontinued in 12 patients.<br /><br />In conclusion, the combination of alectinib and bevacizumab was shown to be safe and highly effective in patients with advanced ALK-rearranged NSCLC. The therapy demonstrated profound and sustained systemic responses, with promising outcomes in patients with brain metastases. These results suggest that antiangiogenic therapy may delay the development of resistance mechanisms and enhance the efficacy of ALK-targeted therapy.

Asset Subtitle

Oscar Arrieta

Meta Tag

Speaker Oscar Arrieta

Topic Metastatic NSCLC: Targeted Therapy - FUSIONS

Keywords

alectinib

bevacizumab

advanced ALK-rearranged NSCLC

combination therapy

efficacy

safety

progression-free survival

overall survival

response rate

adverse events